中文摘要：研究将全合成MUC1糖肽肿瘤疫苗与肌苷酸: 胞苷酸聚合体（poly(I:C)）结合构成了一种新型疫苗，poly(I:C)结构上为一种TLR3-激活佐剂。合成的疫苗可以激活产生额外的IgG抗体滴度，这些抗体可以与人胸部表达肿瘤相关的MUC1的癌症细胞相结合。poly(I:C)糖肽可以诱导产生对抗免疫抑制机制非常重要的促炎性环境，从而可以诱导产生强烈的细胞免疫反应，这对消除肿瘤非常关键。
 
外文摘要：Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, "self-antigens", that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid: cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer cells expressing tumor-associated MUC1. Beside the humoral response, the poly(I:C) glycopeptide vaccine induced a pro-inflammatory environment, very important to overcome the immune-suppressive mechanisms, and elicited a strong cellular immune response crucial for tumor elimination.
外文关键词：antitumor vaccines； cancer immunotherapy； glycopeptides； MUC1； poly(I:C) adjuvant
作者：Glaffig, M; Stergiou, N; Schmitt, E; Kunz, H
作者单位：德国美因兹古腾堡大学
期刊名称：CHEMMEDCHEM
期刊影响因子：3.225
出版年份：2017
出版刊次：5
点击下载：利用Poly(I:C)作为TLR3激活佐剂增强MUC1糖肽肿瘤疫苗的免疫原性